包含干细胞的组合物及其用于卵巢抗衰中的用途
By extracting TP-TOF peptides from sika deer placenta and combining them with stem cells, the problems of high side effects and high costs in existing premature ovarian failure treatments have been solved, achieving effective ovarian function recovery and follicle generation.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZAIYAO (BEIJING) BIOTECHNOLOGY CO LTD
- Filing Date
- 2025-12-18
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments for premature ovarian failure have high risks of side effects from hormone replacement therapy, the effectiveness and safety of gene therapy and immunotherapy need further validation, and they are also costly and lack effective individualized treatment options.
A highly active anti-premature ovarian failure polypeptide, TP-TOF peptide, was isolated from sika deer placenta and combined with a pharmaceutically acceptable carrier to form a drug composition for the treatment of premature ovarian failure, in combination with stem cell therapy to promote ovarian function recovery.
TP-TOF peptides can significantly reduce ovarian granulosa cell apoptosis, increase estradiol and follicle-stimulating hormone levels, shorten the interestrus period, and promote follicle generation. The effect is even more significant when combined with stem cell therapy.
Smart Images
Figure CN121609759B_ABST